Gossamer Bio (NASDAQ:GOSS) Price Target Lowered to $10.00 at Raymond James

Gossamer Bio (NASDAQ:GOSSGet Rating) had its target price reduced by research analysts at Raymond James from $19.00 to $10.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Raymond James’ price objective would indicate a potential upside of 10.13% from the company’s current price.

Other research analysts have also issued reports about the stock. UBS Group began coverage on shares of Gossamer Bio in a research note on Wednesday, April 6th. They issued a “buy” rating and a $19.00 price objective for the company. Barclays cut their price objective on shares of Gossamer Bio from $18.00 to $12.00 in a report on Tuesday. HC Wainwright lowered their price objective on shares of Gossamer Bio from $25.00 to $20.00 in a research report on Tuesday. Sumitomo Mitsui Financial Group raised shares of Gossamer Bio from a “neutral” rating to an “outperform” rating and set a $24.00 price objective for the company in a research note on Monday, January 10th. Finally, Zacks Investment Research upgraded shares of Gossamer Bio from a “sell” rating to a “hold” rating in a report on Tuesday, March 8th. One equities research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, Gossamer Bio presently has a consensus rating of “Buy” and a consensus target price of $18.11.

GOSS stock opened at $9.08 on Tuesday. Gossamer Bio has a 1-year low of $6.65 and a 1-year high of $14.30. The firm has a market cap of $694.41 million, a PE ratio of -2.91 and a beta of 1.03. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 1.47. The business’s 50-day moving average price is $9.08 and its two-hundred day moving average price is $10.50.

Gossamer Bio (NASDAQ:GOSSGet Rating) last released its earnings results on Thursday, March 3rd. The company reported ($0.74) earnings per share for the quarter, hitting the consensus estimate of ($0.74). During the same period in the prior year, the firm earned ($0.88) EPS. On average, analysts forecast that Gossamer Bio will post -3.09 earnings per share for the current year.

In other Gossamer Bio news, CEO Faheem Hasnain sold 19,035 shares of the company’s stock in a transaction on Wednesday, March 23rd. The stock was sold at an average price of $8.91, for a total value of $169,601.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Laura Carter sold 5,002 shares of the firm’s stock in a transaction dated Wednesday, March 16th. The shares were sold at an average price of $8.28, for a total value of $41,416.56. The disclosure for this sale can be found here. Insiders sold a total of 41,038 shares of company stock valued at $358,542 over the last three months. Insiders own 23.30% of the company’s stock.

Several large investors have recently bought and sold shares of the company. Close Asset Management Ltd acquired a new position in shares of Gossamer Bio during the 3rd quarter worth approximately $72,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Gossamer Bio by 26.6% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,193 shares of the company’s stock worth $115,000 after buying an additional 2,772 shares during the period. GSA Capital Partners LLP purchased a new position in shares of Gossamer Bio in the 3rd quarter valued at approximately $133,000. Belvedere Trading LLC purchased a new stake in shares of Gossamer Bio in the fourth quarter valued at approximately $145,000. Finally, Allspring Global Investments Holdings LLC purchased a new stake in Gossamer Bio during the fourth quarter worth $165,000. Hedge funds and other institutional investors own 71.59% of the company’s stock.

About Gossamer Bio (Get Rating)

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colonystimulating factor 1 receptor, or CSF1R, and c-KIT inhibitor for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule for the treatment of inflammatory bowel disease; GB5121, an oral, irreversible, covalent, small molecule inhibitor of Bruton's Tyrosine Kinase for the treatment of primary central nervous system lymphoma; and GB7208, an oral, small molecule, BTK inhibitor for the treatment of multiple sclerosis.

Featured Articles

Analyst Recommendations for Gossamer Bio (NASDAQ:GOSS)

Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.